Influence of Physician-Pharmaceutical Industry Interaction upon Research (의사-제약회사 상호관계가 연구에 미치는 영향)

Kim， Seong Who (김승후); 홍정화; Kim, Ock Joo (김옥주)

doi:10.35301/ksme.2011.14.3.343

Influence of Physician-Pharmaceutical Industry Interaction upon Research

Korean Journal of Medical Ethics
Abbr : 의료윤리
2011, 14(3), pp.343~360
DOI : 10.35301/ksme.2011.14.3.343
Publisher : The Korean Society For Medical Ethics
Research Area : Medicine and Pharmacy > General Medicine
Published : September 30, 2011

Kim， Seong Who ¹, 홍정화 ², Kim, Ock Joo ²

¹울산대학교
²서울대학교

Accredited

ABSTRACT

This article examines the influence of physician-pharmaceutical industry interaction upon medical research. We analyze some of the problems arising from pharmaceutical companies’ sponsorship of clinical trials, such as biased results caused by multiple trials with predictable outcomes and publication biases. Furthermore, we propose specific measures to address and overcome these problems.

KEYWORDS

physician-pharmaceutical industry interaction, research ethics, conflict of interest, sponsor-initiated clinical trials

Citation status

* References for papers published after 2023 are currently being built.

[journal] Angell M / 2008 / Industry-sponsored clinical research: a broken system / JAMA 300 : 1069~1071

[journal] Bekelman JE / 2003 / Scope and impact of financial conflicts of interest in biomedical research: a systematic review / JAMA 289 : 454~465

[book] Bernard Lo / 2009 / Committee on Conflict of Interest in Medical Research, Education, and Practice; Institute of Medicine, Conflict of Interest in Medical Research, Education, and Practice / The National Academies Press

[journal] Bourgeois FT / 2010 / Outcome reporting among drug trials registered in ClinicalTrials.gov / Ann Intern Med 153 : 158~166

[journal] Bruce MP / 2005 / COX-2 inhibitors - lessons in drug safety / N Engl J Med 352 : 1133~1135

[journal] DeAngelis CD / 2010 / Ensuring integrity in industry-sponsored research. Primum non nocere, revisited / JAMA 303 : 1196~1198

[journal] DeAngelis CD / 2008 / Impugning the integrity of medical science: the adverse effects of industry influence / JAMA 299(15) : 1833~1835

[other] Department of Health and Human Services, USA / 2001 / Office of Inspector General, The Globalization of Clinical Trials A Growing Challenge in Protecting Human Subjects. 2001 OEI-01-00-00190

[journal] Doucet M / 2008 / Evaluating solutions to sponsorship bias / J Med Ethics 34 : 627~630

[journal] Drazen JM / 2002 / Institutions, contracts, and academic freedom / N Engl J Med 347 : 1362~1363

[journal] Dunn C / 2002 / Protecting study volunteers in research / Thomson Center Watch : 141~149

[journal] Dyer O / 2004 / GlaxoSmithKline faces US lawsuit over concealment of trial results / BMJ 328(7453) : 1395~

[journal] Dyer O / 2004 / GlaxoSmithKline to set up comprehensive online clinical trials register / BMJ 329(7466) : 590~

[journal] Bombardier / 2000 / Comparison of upper gastrointestinal toxicity of Rofecoxib and Naproxen in patients with rheumatoid arthritis / N Engl J Med 343 : 1520~1528

[journal] Fontanarosa PB / 2005 / Reporting conflicts of interest, financial aspects of research, and role of sponsors in funded studies / Journal of American Medical Association 294 : 110~111

[journal] Gottlieb S / 2001 / Researchers deny any attempt to mislead the public over JAMA article on arthritis drug / BMJ 323 : 301~

[book] Hampson LA / 2008 / Empirical Data on Conflicts of Interest, in The Oxford Textbook of Clinical Research Ethics / Oxford University Press : 767~779

[journal] Hrachovec JB / 2001 / Letter: Reporting of 6-month vs 12-month data in a clinical trial of celecoxib / JAMA 286 : 2398~

[web] / http://grants.nih.gov/grants/policy/coi/ / http://grants.nih.gov/grants/policy/coi/

[web] / http://www.ich.org/ / http://www.ich.org/

[web] / http://www.icmje.org/ethical_4conflicts.html / http://www.icmje.org/ethical_4conflicts.html.

[web] / http://www.icmje.org/publishing_10register.html / http://www.icmje.org/publishing_10register.html

[journal] Juni P / 2004 / Risk of cardiovascular events and rofecoxib: cumulative meta-analysis / The Lancet 364 : 2021~2029

[journal] Kondro W / 2004 / Drug company experts advised staff to withhold data about SSRI use in children / CMAJ 170(5) : 783~

[journal] Liebson P / 2010 / The thiazolidinedione controversy in cardiovascular risk / Preventive Cardiology 13(4) : 209~212

[journal] Matcham J / 2011 / Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry-sponsored clinical trials / Pharmaceut Statist 10 : 70~73

[journal] Melander H / 2003 / Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications / BMJ 326 : 1711~

[journal] Miller FG / 2002 / Ethical assessment of industry-sponsored clinical trials: a case analysis / Chest 121 : 1337~1342

[journal] Psaty BM / 2008 / Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation / JAMA 299(15) : 1813~1817

[journal] Pyke S / 2011 / The potential for bias in reporting of industry-sponsored clinical trials / Pharmaceut Statist 10 : 74~79

[journal] Rennie D / 1997 / Thyroid storm / JAMA 277 : 1238~1243

[journal] Wise J / 1997 / Research suppressed for seven years by drug company / BMJ 314 : 1145~

[journal] Ross JS / 2008 / Guest authorship and ghost writing in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation / JAMA 299(15) : 1800~1812

[journal] Silverstein FE / 2001 / Letter: Reporting of 6-month vs 12-month data in a clinical trial of celecoxib / JAMA 286 : 2399~

[journal] Song F / 2010 / Dissemination and publication of research findings: an updated review of related biases / Health Technology Assessment 14 : 1~220

[journal] Steinbrook R / 2005 / Gag clauses in clinical-trial agreements / The New England Journal of Medicine 352 : 2160~2162

[journal] Whittington DJ / 2004 / Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data / Lancet 363 : 1341~1345

[journal] Wright JM / 2001 / Letter: Reporting of 6-month vs 12-month data in a clinical trial of celecoxib / JAMA 286 : 2398~2399

[journal] Wynia M / 2009 / Better regulation of industry-sponsored clinical trials is long overdue. The Journal of Law / Medicine & Ethics 37(3) : 395~419

This paper was written with support from the National Research Foundation of Korea.

KJCKorea
Journal Central

Korean Journal of Medical Ethics 2023 KCI Impact Factor : 1.21

Influence of Physician-Pharmaceutical Industry Interaction upon Research

ABSTRACT

KEYWORDS

Citation status

* References for papers published after 2023 are currently being built.

Korean Journal of Medical Ethics 2023 KCI Impact Factor : 1.21

Influence of Physician-Pharmaceutical Industry Interaction upon Research

ABSTRACT

KEYWORDS

Statistics

Tools

Issue List

Citation status

KCI Citation Counts (5)

REFERENCES (39) * References for papers published after 2023 are currently being built.

Search PDF

Citation

* References for papers published after 2023 are currently being built.